← Leaderboards
Sattva S Neelapu
University Of Tx Md Anderson Can Ctr
$3,334,171
Attributed
$5,555,824
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,555,824 · 4
By mechanism
R01$4,443,307 · 2
R21$568,197 · 1
K23$544,320 · 1
Top collaborators
- Richard Eric Davis4 shared
- David R Piwnica-Worms4 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Richard Eric Davis$942,457
- Ken Chen$2,559,193
- Laszlo George Radvanyi$2,629,361
- Powel Brown$21,822,596
- Paolo Strati$189,338
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorResponseCellsImmunotherapyGenerationsProteinsMelanomaRelapseImmune ResponseLymphomaB-LymphocytesT-LymphocyteImmuneDisease RemissionMolecularImmunogenicImmunoglobulin IdiotypesPre-ClinicalFollicular LymphomaImmunologic MonitoringMalignant NeoplasmsDisease-Free SurvivalCancer PatientB-Cell Lymphomas
Grant awards (14)
[18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events$1,109,154
R01 · FY2025 · CA
[18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events$516,653
R01 · FY2024 · CA
[18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events$561,726
R01 · FY2023 · CA
[18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events$526,490
R01 · FY2022 · CA
Predictors of clinical outcome after therapeutic vaccination in follicular lympho$274,863
R01 · FY2014 · CA · contact PI
Predictors of clinical outcome after therapeutic vaccination in follicular lympho$465,019
R01 · FY2013 · CA · contact PI
Predictors of clinical outcome after therapeutic vaccination in follicular lympho$494,701
R01 · FY2012 · CA · contact PI
Predictors of clinical outcome after therapeutic vaccination in follicular lympho$494,701
R01 · FY2011 · CA · contact PI
Enhancing antitumor immunity with anti-PD-1 antibody in follicular lymphoma.$279,772
R21 · FY2011 · CA · contact PI
Enhancing antitumor immunity with anti-PD-1 antibody in follicular lymphoma.$288,425
R21 · FY2010 · CA · contact PI
Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy$136,080
K23 · FY2010 · CA · contact PI
Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy$136,080
K23 · FY2009 · CA · contact PI
Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy$136,080
K23 · FY2008 · CA · contact PI
Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy$136,080
K23 · FY2007 · CA · contact PI